Article Details

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 ... - PR Newswire

Retrieved on: 2022-10-28 00:28:58

Tags for this article:

Click the tags to see associated articles and topics

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 ... - PR Newswire. View article details on hiswai:

Excerpt

"ADX-914 represents a potential unique approach to correcting immune system dysregulation," said Elizabeth H.Z. Thompson, Ph.D., Executive Vice ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up